Ulrik Lassen, MD, PhD, discusses the updated response findings with larotrectinib in TRK+ cancers.
Ulrik Lassen, MD, PhD, professor, Department of Oncology, Rigshospitalet, Copenhagen, discusses the updated response findings with larotrectinib in TRK+ cancers.
In a pooled analysis of adult and pediatric patients with advanced cancers associated withNTRKgene fusions, the TRK inhibitor larotrectinib had an 80% objective response rate. The most recent follow-up data showed complete responses in 10 of 55 patients and partial responses in 34. This pooled analysis consisted of 3 studies in multiple tumor types and across the age range from infants to older adults.
According to Lassen, larotrectinib continues to demonstrate robust tumor-agnostic and age-agnostic antitumor activity against TRK fusion cancers, regardless of theNTRKgene or fusion partner involved. Although NTRK
Nogapendekin Alfa Plus Checkpoint Inhibition Improves Survival in NSCLC
April 25th 2024Following its recent FDA approval in non-muscle-invasive bladder cancer, nogapendekin alfa has also shown overall survival benefits in addition to checkpoint inhibitor therapy in patients with non-small cell lung cancer.
Read More
Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC
April 16th 2024At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).
Read More